Top Regulatory News Stories – Week Ending September 22, 2017

This week the FDA approved two new molecular entities and the EC approved four new programs. Several new orphan drug designations were granted along with a fast track designation.  Here are the top regulatory news stories this week:

Bayer received FDA Approval for Aliqopa™ (copanlisib) 60 mg vial for Injection in adults with Relapsed Follicular Lymphoma after two prior systemic therapies. Accelerated approval was granted for this indication based on objective response rate.  http://www.prnewswire.com/news-releases/bayer-receives-fda-approval-for-aliqopa-copanlisib-60-mg-vial-for-injection-in-adults-with-relapsed-follicular-lymphoma-after-two-prior-systemic-therapies-300520109.html

Symbiomix Therapeutics announced that the FDA has approved Solosec™ (secnidazole) 2g oral granules for the treatment of bacterial vaginosis (BV) in adult women.  https://symbiomix.com/fda-approves-symbiomix-therapeutics-solosec-secnidazole-oral-granules-treatment-bacterial-vaginosis-adult-women/

GSK and Innoviva have secured approval from the FDA for once-daily and single inhaler triple therapy, Trelegy Ellipta, to treat patients with COPD. http://regulatoryaffairs.pharmaceutical-business-review.com/news/gsk-innoviva-get-fda-nod-for-copd-treatment-trelegy-ellipta-200917-5929780

Ipsen announced that the European Commission (EC) has approved Xermelo (telotristat ethyl) 250 mg three times a day (tid) for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analogue (SSA) therapy in adults inadequately controlled by SSA therapy. http://www.pharmaceutical-business-review.com/news/ipsen-gets-ec-approval-for-xermelo-to-treat-carcinoid-syndrome-diarrhea-200917-5929806

Novartis’ cancer drug Rydapt (midostaurin) has been approved by the European Commission (EC) for a mutated form of acute myeloid leukemia (AML) and certain rare blood disorders. http://regulatoryaffairs.pharmaceutical-business-review.com/news/novartis-rydapt-approved-in-europe-for-aml-and-rare-blood-disorders-210917-5930884

Roche has secured approval from the European Commission (EC) for its Gazyvaro (obinutuzumab) in combination with chemotherapy for the treatment for previously untreated advanced follicular lymphoma. http://regulatoryaffairs.pharmaceutical-business-review.com/news/roche-gets-ec-nod-for-gazyvaro-to-treat-advanced-follicular-lymphoma-220917-5932107

Merck and Pfizer have secured the approval of their skin cancer drug Bavencio (avelumab) from the European Commission (EC) as a monotherapy for the treatment of metastatic Merkel cell carcinoma (mMCC) in adults. http://regulatoryaffairs.pharmaceutical-business-review.com/news/merck-pfizer-get-ec-approval-for-bavencio-for-metastatic-merkel-cell-carcinoma-220917-5931996

The FDA granted Fast Track Designation for Amicus Therapeutics’ Migalastat for treatment of Fabry Disease. This comes less than a year after the FDA forced Amicus to mount a special trial to collect GI data.  https://finance.yahoo.com/news/u-fda-grants-fast-track-113000651.html

The FDA has granted Motif Bio’s investigational drug candidate, iclaprim, orphan drug designation to treat of Staphylococcus aureus lung infections in patients with cystic fibrosis. http://regulatoryaffairs.pharmaceutical-business-review.com/news/fda-grants-orphan-drug-status-for-motif-bios-iclaprim-to-treat-staphylococcus-aureus-lung-infections-in-patients-with-cystic-fibrosis-190917-5928703

Amylyx Pharmaceuticals announced that the FDA has granted orphan drug designation to AMX0035, an oral therapeutic in clinical development for the treatment of amyotrophic lateral sclerosis (ALS). https://www.firstwordpharma.com/node/1506278

ProQR received orphan drug designation from FDA for their drug candidate QR-313 for Dystrophic Epidermolysis Bullosa https://www.firstwordpharma.com/node/1506245

PhaseRx, Inc. announced that its second drug development candidate, PRX-ASL, for the treatment of argininosuccinate lyase deficiency (ASLD), has received orphan drug designation by the FDA.  https://www.firstwordpharma.com/node/1506806

Sunovion submitted an NDA to the FDA for Dasotraline for the treatment of patients with ADHD https://www.drugs.com/nda/dasotraline_170831.html

Boehringer Ingelheim announced that the Committee for Medicinal Products for Human Use (CHMP) of EMA has adopted a positive opinion for the Marketing Authorization Application of Cyltezo (adalimumab biosimilar), to treat multiple chronic inflammatory diseases in adults and children. http://regulatoryaffairs.pharmaceutical-business-review.com/news/boehringer-ingelheim-receives-positive-chmp-opinion-for-adalimumab-biosimilar-cyltezo-180917-5927639

The CHMP also recommended GSK and Innoviva’s fluticasone furoate/ umeclidinium/vilanterol (FF/UMEC/VI) in treating chronic obstructive pulmonary disease (COPD) in adults. http://processandproduction.pharmaceutical-business-review.com/news/chmp-recommends-gsk-innovivas-single-inhaler-triple-therapy-for-copd-180917-5927633

CSL Behring announced that the FDA has approved Privigen®[Immune Globulin Intravenous (Human), 10% Liquid] for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability. Privigen was initially approved in 2007 for treatment of Primary Immunodeficiency Syndrome. https://www.firstwordpharma.com/node/1505298

Janet Woodcock, Director of FDA’s Center for Drug Evaluation and Research, said that the clinical trials system is “broken” and there needs to be new ways to collect and utilize patient data:  http://raps.org/Regulatory-Focus/News/2017/09/20/28500/FDAs-Woodcock-The-Clinical-Trials-System-is-Broken/

In other news…

Ultragenyx proposes to acquire Dimension Therapeutics.  This comes two weeks after the announced acquisition of Dimension by RegenxBio:  http://drugdiscovery.pharmaceutical-business-review.com/news/ultragenyx-proposes-to-acquire-dimension-therapeutics-190917-5928690  

 Alnylam Pharmaceuticals said Wednesday a Phase 3 study testing its experimental therapeutic patisiran met all of its primary and secondary objectives in a rare and debilitating genetic disease:  http://www.biopharmadive.com/news/alnylam-soars-apollo-trial-success-patisiran-rnai/505308/

Pfizer is suing J&J over contracts blocking Remicade biosimilars:  http://raps.org/Regulatory-Focus/News/2017/09/20/28498/Pfizer-Sues-JJ-Over-Contracts-Blocking-Remicade-Biosimilars

Spark Therapeutics announced it has entered into a licensing agreement with Genethon, a non-profit research and development organization, for the development and commercialization of an adeno-associated viral (AAV) gene therapy targeting the liver to address a rare genetic disease.  https://www.firstwordpharma.com/node/1506586

 

This is a weekly recap of selected industry news stories. You can read other additional blogs, see our recent job postings and learn more about us at www.dennispartners.com

Leave a Reply

Your email address will not be published. Required fields are marked *